Table 1

Nomenclature differs between agencies

EMA:FDA:
Biosimilarity is decided by EMA, interchangeability is decided by individual member states

  • Remicade: Infliximab

  • Remsima: Infliximab

  • Enbrel: Etanercept

  • Benepali: Etanercept

  • Humira: Adalimumab

  • Solymbic: Adalimumab

Prescription by brand to distinguish actual product given to patients and allow pharmacovigilance		Interchangeability requires additional information with regard to biosimilarity; Suffix strategy to identify 

  • Remicade: Infliximab

  • Inflectra: Infliximab dyyb

  • Enbrel: Etanercept

  • Erelzi: Etanercept szzs

  • Humira: Adalimumab

  • Amjevita: Adalimumab atto